Enanta Pharmaceuticals | ENTA - Operating Expenses


Enanta Pharmaceuticals reported $126.59M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Amgen USD 5.9B 773M Dec/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Immunic USD 25.73M 2.91M Sep/2024
Incyte USD 1.12B 3.53B Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Merck USD 10.16B 558M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Novavax USD 218.53M 34.86M Sep/2024
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025